vs
ICU MEDICAL INC（ICUI）与MSC INDUSTRIAL DIRECT CO INC（MSM）财务数据对比。点击上方公司名可切换其他公司
MSC INDUSTRIAL DIRECT CO INC的季度营收约是ICU MEDICAL INC的1.8倍（$965.7M vs $540.7M），MSC INDUSTRIAL DIRECT CO INC净利率更高（5.4% vs -2.9%，领先8.3%），MSC INDUSTRIAL DIRECT CO INC同比增速更快（4.0% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $7.4M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -3.4%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
MSC工业直销公司（MSC）通过旗下主要子公司MSC工业供应公司，是美国规模最大的工业设备分销商之一，可提供超过150万种金属加工及其他工业类产品，广泛服务于工业制造、维修运维等领域的客户需求。
ICUI vs MSM — 直观对比
营收规模更大
MSM
是对方的1.8倍
$540.7M
营收增速更快
MSM
高出18.2%
-14.1%
净利率更高
MSM
高出8.3%
-2.9%
自由现金流更多
ICUI
多$28.5M
$7.4M
两年增速更快
ICUI
近两年复合增速
-3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $965.7M |
| 净利润 | $-15.7M | $51.8M |
| 毛利率 | 37.5% | 40.7% |
| 营业利润率 | 1.0% | 7.9% |
| 净利率 | -2.9% | 5.4% |
| 营收同比 | -14.1% | 4.0% |
| 净利润同比 | 34.0% | 11.1% |
| 每股收益（稀释后） | $-0.63 | $0.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIMSM
| Q4 25 | $540.7M | $965.7M | ||
| Q3 25 | $537.0M | $978.2M | ||
| Q2 25 | $548.9M | $971.1M | ||
| Q1 25 | $604.7M | — | ||
| Q4 24 | $629.8M | $928.5M | ||
| Q3 24 | $589.1M | — | ||
| Q2 24 | $596.5M | $979.4M | ||
| Q1 24 | $566.7M | $935.3M |
净利润ICUIMSM
| Q4 25 | $-15.7M | $51.8M | ||
| Q3 25 | $-3.4M | $56.5M | ||
| Q2 25 | $35.3M | $56.8M | ||
| Q1 25 | $-15.5M | — | ||
| Q4 24 | $-23.8M | $46.6M | ||
| Q3 24 | $-33.0M | — | ||
| Q2 24 | $-21.4M | $71.7M | ||
| Q1 24 | $-39.5M | $61.8M |
毛利率ICUIMSM
| Q4 25 | 37.5% | 40.7% | ||
| Q3 25 | 37.4% | 40.4% | ||
| Q2 25 | 37.9% | 41.0% | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | 40.7% | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | 40.9% | ||
| Q1 24 | 32.7% | 41.5% |
营业利润率ICUIMSM
| Q4 25 | 1.0% | 7.9% | ||
| Q3 25 | 2.6% | 8.6% | ||
| Q2 25 | 1.9% | 8.5% | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 6.0% | 7.8% | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.3% | 10.9% | ||
| Q1 24 | -1.9% | 9.7% |
净利率ICUIMSM
| Q4 25 | -2.9% | 5.4% | ||
| Q3 25 | -0.6% | 5.8% | ||
| Q2 25 | 6.4% | 5.9% | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | -3.8% | 5.0% | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.6% | 7.3% | ||
| Q1 24 | -7.0% | 6.6% |
每股收益（稀释后）ICUIMSM
| Q4 25 | $-0.63 | $0.93 | ||
| Q3 25 | $-0.14 | $1.02 | ||
| Q2 25 | $1.43 | $1.02 | ||
| Q1 25 | $-0.63 | — | ||
| Q4 24 | $-0.97 | $0.83 | ||
| Q3 24 | $-1.35 | — | ||
| Q2 24 | $-0.88 | $1.27 | ||
| Q1 24 | $-1.63 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $40.3M |
| 总债务越低越好 | — | $214.1M |
| 股东权益账面价值 | $2.1B | $1.4B |
| 总资产 | $4.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.16× |
8季度趋势，按日历期对齐
现金及短期投资ICUIMSM
| Q4 25 | — | $40.3M | ||
| Q3 25 | — | $56.2M | ||
| Q2 25 | — | $71.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | $57.3M | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | $25.9M | ||
| Q1 24 | $251.4M | $22.2M |
总债务ICUIMSM
| Q4 25 | — | $214.1M | ||
| Q3 25 | — | $168.8M | ||
| Q2 25 | — | $285.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $289.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $299.8M | ||
| Q1 24 | — | $294.5M |
股东权益ICUIMSM
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | $1.4B | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | $1.4B | ||
| Q1 24 | $2.1B | $1.4B |
总资产ICUIMSM
| Q4 25 | $4.1B | $2.5B | ||
| Q3 25 | $4.1B | $2.5B | ||
| Q2 25 | $4.1B | $2.5B | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.2B | $2.5B | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.3B | $2.5B | ||
| Q1 24 | $4.3B | $2.5B |
负债/权益比ICUIMSM
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $29.4M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $7.4M |
| 自由现金流率自由现金流/营收 | 6.6% | 0.8% |
| 资本支出强度资本支出/营收 | 4.6% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 0.57× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIMSM
| Q4 25 | $60.6M | $29.4M | ||
| Q3 25 | $56.7M | — | ||
| Q2 25 | $11.2M | $151.6M | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $40.2M | $101.9M | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $82.0M | $143.5M | ||
| Q1 24 | $45.8M | $78.7M |
自由现金流ICUIMSM
| Q4 25 | $36.0M | $7.4M | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | $100.7M | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | $81.7M | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | $114.0M | ||
| Q1 24 | $29.9M | $53.4M |
自由现金流率ICUIMSM
| Q4 25 | 6.6% | 0.8% | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | 10.4% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | 8.8% | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | 11.6% | ||
| Q1 24 | 5.3% | 5.7% |
资本支出强度ICUIMSM
| Q4 25 | 4.6% | 2.3% | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | 5.2% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | 2.2% | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 2.8% | 2.7% |
现金转化率ICUIMSM
| Q4 25 | — | 0.57× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | 2.67× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.00× | ||
| Q1 24 | — | 1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
MSM
暂无分部数据
